This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Cyfuse Biomedical KK's Median PS Value or its related term are showing as below:
TSE:4892's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.87 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Cyfuse Biomedical KK (TSE:4892) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Cyfuse Biomedical KK's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
552.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK Median PS Value Related Terms
Cyfuse Biomedical KK Median PS Value Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Cyfuse Biomedical KK's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3.498.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK (TSE:4892) has a Median PS Value of 円0.00 as of Jul. 13, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cyfuse Biomedical KK and its competitors. According to the industry distribution chart, Cyfuse Biomedical KK ranks #999999 out of 544 companies in the Drug Manufacturers industry.
Is Cyfuse Biomedical KK's Median PS Value too high?
Cyfuse Biomedical KK's current Median PS Value is 円0.00. Based on the distribution chart, Cyfuse Biomedical KK ranks #999999 out of 544 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #999999 out of 544 companies for Median PS Value. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median Median PS Value is 0.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Median PS Value is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,179.63, compared to a current price of 円552.00 — trading 74.7% below its estimated fair value. The current Median PS Value is 円0.00. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Median PS Value is 円0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円552.00 is trading 74.7% below its estimated GF Value™ of 円2,179.63.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Median PS Value: 円0.00
GF Value™: 円2,179.63 vs. price of 円552.00 (74.7% below fair value)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
